標題: 日股..製薬..Otsuka Holdings 大塚製薬(日股 4578,美股 OTSKY,OTSKF)
kaka
同學




UID 6717
精華 0
積分 0
帖子 6266
閱讀權限 99
註冊 2014-5-7
用戶註冊天數 3614
用戶失蹤天數 1720

111.83.200.104
分享 
發表於 2017-11-4 18:44  資料 私人訊息 
日股..製薬..Otsuka Holdings 大塚製薬(日股 4578,美股 OTSKY,OTSKF)
日股..Otsuka Holdings 大塚製薬株式会社(日股 4578,美股 OTSKY,OTSKF)


http://www.otsuka.com


https://en.wikipedia.org/wiki/Otsuka_Pharmaceutical


Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.


OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company.[1] The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.[1]


In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".[2] This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.[3]


In September 2013, Otsuka Holdings announced it had agreed to acquire Astex Pharmaceuticals for close to $900 million.[4]


In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.[5]


In March 2017, the company agreed to acquire Neurovance, inc for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.[6]


The company has sponsored Tokushima Vortis, a football club in Naruto.
頂部